Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306821 | 0.90 | CXCR4 (0.45) | CXCR4MEN1KMT2A | |
| SCHEMBL2470094 | 0.87 | CXCR4 (0.42) | CXCR4CYP11B1CYP11B2CYP19A1DRD4 | |
| SCHEMBL8301581 | 0.84 | CXCR4 (0.41) | CXCR4MEN1KMT2A | |
| SCHEMBL2475017 | 0.84 | CXCR4 (0.41) | CXCR4MEN1KMT2A | |
| SCHEMBL11983265 | 0.84 | CXCR4 (0.41) | CXCR4CYP19A1KDM4EMEN1KMT2A | |
| SCHEMBL2472770 | 0.84 | CXCR4 (0.43) | CXCR4MEN1KMT2A | |
| SCHEMBL2474601 | 0.82 | PDE2A (0.42) | CXCR4PDE2A | |
| SCHEMBL2472931 | 0.82 | CXCR4 (0.40) | CXCR4CYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL2473381 | 0.82 | CXCR4 (0.40) | CXCR4CYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL2476263 | 0.81 | CYP11B1 (0.44) | CXCR4CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664617-A1 | Method of making a 2,6-diaryl piperidine derivative | Genzyme Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1615633-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | CXCR4 2190/4885CHRM1 2733/4885CYP11B1 570/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | CXCR4 1/4885CHRM1 918/4885CYP11B1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.